Findings

What do systematic reviews say?

131 questions · 132 findings · 7 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 18 · 13.6%GRADE not reported 2 · 1.5%Very low 38 · 28.8%Low 43 · 32.6%Moderate 27 · 20.5%High 4 · 3%

Ocrelizumab vs interferon beta‐1a

Number of participants with any adverse events · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any adverse events compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
RR 1 [0.96, 1.04]
2 studies · 1651 participants
Moderate

Ocrelizumab vs interferon beta‐1a

Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
RR 0.79 [0.57, 1.11]
2 studies · 1651 participants
Low

Ocrelizumab vs interferon beta‐1a

Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
RR 0.58 [0.37, 0.91]
2 studies · 1651 participants
Low

Ocrelizumab vs interferon beta‐1a

Number of participants with gadolinium‐enhancing T1 lesions on MRI · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants with gadolinium‐enhancing T1 lesions on MRI compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
RR 0.27 [0.22, 0.35]
2 studies · 1656 participants
Low

Ocrelizumab vs interferon beta‐1a

Number of participants with new or enlarging T2‐hyperintense lesions on MRI · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants with new or enlarging T2‐hyperintense lesions… compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
RR 0.63 [0.57, 0.69]
2 studies · 1656 participants
Low

Fingolimod 0.5 mg vs interferon beta‐1a

Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg showed no clear difference in withdrawals due to adverse events compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.51 [0.81, 2.8]
1 study · 860 participants
Moderate

Fingolimod 0.5 mg vs interferon beta‐1a

Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
Rate ratio 0.48 [0.34, 0.7]
1 study · 860 participants
Moderate

Fingolimod 0.5 mg vs interferon beta‐1a

Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg probably leads to higher participants free from MRI gadolinium‐enhancing lesions compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.12 [1.05, 1.19]
1 study · 728 participants
Moderate

Fingolimod 0.5 mg vs interferon beta‐1a

Outcomes at 12 months · patients with relapsing‐remitting multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fingolimod 0.5 mg vs interferon beta‐1a

Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.18 [1.09, 1.27]
1 study · 860 participants
Moderate

Fingolimod 0.5 mg vs interferon beta‐1a

Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg showed no clear difference in participants free from disability worsening compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.02 [0.99, 1.06]
1 study · 860 participants
Low